# Immune Control

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immune-control

- Industry: Pharmaceuticals
- Headquarters: US
- Total disclosed funding: $11M
- Latest round: Series A (Jul 14, 2005)
- Investors on record: 5

## About

Immune Control, Inc. engages in development of drugs to stop undesirable proliferation of immune cells.

## Funding rounds

- Series A, Jul 14, 2005, $11M — Domain Associates, Quaker Partners Management, Anthem Capital, NewSpring, BioAdvance

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series A
- Anthem Capital (https://capitalatlas.ai/funds/anthem-capital) — Series A
- NewSpring (https://capitalatlas.ai/funds/newspring) — Series A
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series A